Understanding genetics in cannabis use disorder and response to cannabinoids
Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans
This study is testing how genetics affect the risk of cannabis use disorder and how people respond to a treatment with Delta-9-THC compared to a placebo.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 215 (estimated) |
| Ages | 21 Years to 60 Years |
| Sex | All |
| Sponsor | Yale University Academic / other |
| Locations | 1 site (West Haven, Connecticut) |
| Trial ID | NCT06058702 on ClinicalTrials.gov |
What this trial studies
This study investigates how genetic factors influence an individual's risk for cannabis use disorder (CanUD) and their response to cannabinoids. It aims to explore the relationship between genetics and the development of CanUD, as well as the effectiveness of treatments for this condition. Participants will receive either Delta-9-THC or a placebo to assess their responses. The research is particularly relevant given the increasing prevalence of cannabis use and its associated risks.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 21-60 who are experiencing issues related to cannabis use disorder.
Not a fit: Patients with major medical conditions, cannabis-naïve individuals, or those who are pregnant will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to personalized treatment strategies for individuals with cannabis use disorder based on their genetic profiles.
How similar studies have performed: While there have been studies on cannabis use disorder, this specific genetic approach is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: -Ages 21-60 years old Exclusion Criteria: * Major or unstable medical conditions based on history, the Structured Clinical Interview for DSM-5, collateral information, physical and laboratory examinations, ECG, and vital signs. * Cannabis naïve individuals * Positive pregnancy test
Where this trial is running
West Haven, Connecticut
- West Haven Veterans Affairs Medical Center — West Haven, Connecticut, United States (Recruiting)
Study contacts
- Principal investigator: Deepak D'Souza, MD — Yale University
- Study coordinator: Deepak D'Souza, MD
- Email: deepak.douza@yale.edu
- Phone: 203-932-5711
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.